Indolent Non-hodgkin Lymphoma

• CLINICAL_TRIALS research · 2026-04-20
  Clinical Trial Update: NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers [Phase 1]

  This document outlines an ongoing Phase 1 trial evaluating NKX019, an allogeneic CAR NK cell therapy, in adults with B-cell cancers includin…

• CLINICAL_TRIALS research · 2026-04-09
  Clinical Trial Update: The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients [NA]

  This study examines how structured exercise affects immune phenotype in patients with indolent non-Hodgkin lymphoma and chronic lymphocytic …

• CLINICAL_TRIALS research · 2026-03-23
  Clinical Trial Update: Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma [Phase 1]

  Phase 1 clinical trial evaluating Rituximab plus Bendamustine and ibrutinib (PCI-32765) in relapsed DLBCL, mantle cell lymphoma, and various…

• CLINICAL_TRIALS research · 2026-03-17
  Clinical Trial Update: Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma [Phase 2]

  A Phase 2 clinical trial evaluating CD19 t-haNK and NAI with Rituximab in relapsed indolent non-Hodgkin lymphoma; the study is not yet recru…

• CLINICAL_TRIALS research · 2026-03-13
  Clinical Trial Update: Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma [Phase 2]

  Phase 2 trial evaluating the efficacy and safety of Lisaftoclax (APG-2575) as a monotherapy in indolent lymphomas, including Waldenström mac…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS research · 2026-02-19
  Clinical Trial Update: Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas [Phase 2]

  Phase 2 trial evaluating frontline obinutuzumab and ibrutinib in indolent non-Hodgkin lymphoma is active but not recruiting, per ClinicalTri…

• CLINICAL_TRIALS research · 2026-02-09
  Clinical Trial Update: Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas [Phase 2]

  A Phase 2 clinical trial evaluating the combination of acalabrutinib and obinutuzumab as initial therapy for previously untreated follicular…

• CLINICAL_TRIALS research · 2026-02-06
  Clinical Trial Update: Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma [Phase 2]

  Ongoing Phase 2 trial evaluating nivolumab in combination with DA-REPOCH chemotherapy for aggressive B-cell non-Hodgkin lymphomas, including…

• CLINICAL_TRIALS research · 2026-01-20
  Clinical Trial Update: Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. [Phase 1]

  Phase 1 study evaluating T cells engineered to co-express kappa and CD28 CARs for relapsed/refractory kappa+ non-Hodgkin lymphoma and chroni…

• CLINICAL_TRIALS research · 2025-12-30
  Clinical Trial Update: Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma [Phase 1]

  A Phase 1 trial is evaluating the combination of copanlisib and nivolumab in patients with Richter's transformation or transformed indolent …

• CLINICAL_TRIALS research · 2025-09-15
  Clinical Trial Update: An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment [Phase 1]

  Early-phase trial evaluating a three-drug combination (venetoclax, lenalidomide, and rituximab with hyaluronidase) in relapsed or refractory…

• CLINICAL_TRIALS research · 2025-09-11
  Clinical Trial Update: Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL) [Phase 2]

  Phase 2 trial evaluating ME-401 in relapsed or refractory indolent non-Hodgkin lymphoma; the study is currently active but not recruiting.

• CLINICAL_TRIALS research · 2025-06-27
  Clinical Trial Update: Combating Cancer-Related Fatigue: A Personalized Supportive Care Program [NA]

  This clinical trial update reports a UNC Lineberger Comprehensive Cancer Center study recruiting participants for a personalized supportive …

• CLINICAL_TRIALS research · 2025-01-06
  Clinical Trial Update: MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma [Phase 2]

  A Phase 2 trial exploring MRD-guided de-intensification of Bendamustine plus Rituximab for indolent non-Hodgkin lymphoma; the study is curre…

• CLINICAL_TRIALS research · 2013-12-04
  Clinical Trial Update: Fludara (Oral) Phase II Study for Indolent Lymphoma [Phase 2]

  A Phase II trial of oral fludarabine for indolent non-Hodgkin lymphoma has completed.